Manufacturing of a SARS-CoV-2 virus-like particle vaccine adjuvanted with K3 CpG oligodeoxynucleotide and alhydrogel for phase 1/2 clinical trials

Bulbul, A.; Yilmaz, I. C.; Yilmaz, N.; Turay, N.; Ipekoglu, E. M.; Guvencli, N.; Yildirim, M.; Canavar, T.; Evcili, I.; Bildik, T.; Bartan, A.; Kasa, M. B.; Mookala, N.; Yadav, V.; Sharma, M.; Yannabathina, T. R.; Jadav, V.; Gursel, M.; Gursel, I.

Bulbul, A.; Yilmaz, I. C.; Yilmaz, N.; Turay, N.; Ipekoglu, E. M.; Guvencli, N.; Yildirim, M.; Canavar, T.; Evcili, I.; Bildik, T.; Bartan, A.; Kasa, M. B.; Mookala, N.; Yadav, V.; Sharma, M.; Yannabathina, T. R.; Jadav, V.; Gursel, M.; Gursel, I..

European Journal of Immunology ; 51:370-370, 2021.

Article in English | Web of Science | ID: covidwho-1716862

Keywords

Adaptive immunity; adjuvants and vaccines; infectious disease; innate; immunity; viral infections; Immunology

Search on Google

XML

Collection: Databases of international organizations Database: Web of Science Type of study: Prognostic study Topics: Vaccines Language: English Journal: European Journal of Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML